CD274 and melanoma: Following that, anti-programmed death (PD)-1 antibodies (e.g., pembrolizumab and nivolumab) and anti-programmed death ligand-1 (PD-L1) antibodies (e.g., atezolizumab and durvalumab) were developed and widely used in the treatment of several cancer types, including melanoma, NSCLC, renal cell carcinoma, and head and neck squamous cell carcinoma [13,14,15,16,17].